- Stocks
- Healthcare
- NYSE: MRK

Price (delayed)

$80.86

Market cap

$204.25B

P/E Ratio

28.37

Dividend/share

$2.64

EPS

$2.85

Enterprise value

$220.67B

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the

The P/E is 32% lower than the 5-year quarterly average of 40.7 and 6% lower than the last 4 quarters average of 29.7

Merck's equity has increased by 23% YoY and by 8% from the previous quarter

The net income has declined by 38% year-on-year but it is up by 29% since the previous quarter

The EPS has contracted by 37% YoY but it has grown by 30% from the previous quarter

MRK's gross margin is down by 4.6% year-on-year

What are the main financial stats of MRK

Market
Valuations
Earnings

Shares outstanding

2.53B

Market cap

$204.25B

Enterprise value

$220.67B

Price to earnings (P/E)

28.37

Price to book (P/B)

5.72

Price to sales (P/S)

4.16

EV/EBIT

25.17

EV/EBITDA

18.31

EV/Sales

4.49

Revenue

$49.15B

EBIT

$8.77B

EBITDA

$12.05B

Free cash flow

$8.33B

Per share
Balance sheet
Liquidity

EPS

$2.85

Free cash flow per share

$3.29

Book value per share

$14.14

Revenue per share

$19.42

TBVPS

$24.2

Total assets

$93.49B

Total liabilities

$57.63B

Debt

$26.44B

Equity

$35.79B

Working capital

$7.33B

Debt to equity

0.74

Current ratio

1.31

Quick ratio

0.78

Net debt/EBITDA

1.36

Margins
Efficiency
Dividend

EBITDA margin

24.5%

Gross margin

67.9%

Net margin

14.6%

Operating margin

14.6%

Return on assets

7.9%

Return on equity

23.7%

Return on invested capital

16.1%

Return on capital employed

12.6%

Return on sales

17.8%

Dividend yield

3.26%

DPS

$2.64

Payout ratio

92.6%

How has the Merck stock price performed over time

Intraday

2.17%

1 week

0.14%

1 month

5.6%

1 year

4.92%

YTD

5.51%

QTD

5.51%

How have Merck's revenue and profit performed over time

Revenue

$49.15B

Gross profit

$33.39B

Operating income

$7.2B

Net income

$7.2B

Gross margin

67.9%

Net margin

14.6%

Merck's operating income has soared by 51% from the previous quarter but it has decreased by 36% YoY

MRK's net margin is down by 44% year-on-year but it is up by 23% since the previous quarter

Merck's operating margin has increased by 43% QoQ but it has decreased by 43% YoY

The net income has declined by 38% year-on-year but it is up by 29% since the previous quarter

What is Merck's growth rate over time

What is Merck stock price valuation

P/E

28.37

P/B

5.72

P/S

4.16

EV/EBIT

25.17

EV/EBITDA

18.31

EV/Sales

4.49

The EPS has contracted by 37% YoY but it has grown by 30% from the previous quarter

The P/E is 32% lower than the 5-year quarterly average of 40.7 and 6% lower than the last 4 quarters average of 29.7

Merck's equity has increased by 23% YoY and by 8% from the previous quarter

The price to book (P/B) is 16% lower than the last 4 quarters average of 6.7 and 13% lower than the 5-year quarterly average of 6.4

The revenue has grown by 11% YoY and by 4.7% from the previous quarter

MRK's P/S is 7% below its 5-year quarterly average of 4.4 and 2.9% below its last 4 quarters average of 4.2

How efficient is Merck business performance

Merck's ROE has decreased by 44% YoY but it has increased by 22% from the previous quarter

The ROS has contracted by 41% YoY but it has grown by 22% from the previous quarter

The ROIC fell by 41% YoY but it rose by 28% QoQ

The company's return on assets fell by 40% YoY but it rose by 30% QoQ

What is MRK's dividend history

DPS

$2.64

Dividend yield

3.26%

Payout ratio

92.6%

Recent dividends

How did Merck financials performed over time

The total assets is 62% more than the total liabilities

Merck's total liabilities has decreased by 4.8% YoY

The total assets has grown by 4.1% YoY and by 3.1% from the previous quarter

MRK's debt is 26% smaller than its equity

The debt to equity has contracted by 24% YoY and by 8% from the previous quarter

Merck's equity has increased by 23% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.